The Brain: Alzheimer's and dementia news and discussions

[weatheriscool]

[weatheriscool]

[weatheriscool]

[weatheriscool]

[weatheriscool]

[weatheriscool]

[weatheriscool]

[firestar464]

Sex differences in dementia risks reveal stronger cognitive impacts in women

https://medicalxpress.com/news/2026-05- ... onger.html

[weatheriscool]

[weatheriscool]

[weatheriscool]

[wjfox]

[weatheriscool]

[firestar464]

More on that here:

https://www.economist.com/briefing/2026 ... g-defeated

[weatheriscool]

[wjfox]

[firestar464]

[weatheriscool]

FDA approves first Alzheimer's blood test for Americans as young as 40
By Bronwyn Thompson
August 23, 2026
https://newatlas.com/brain/alzheimers-d ... lood-test/

In a move that could help drastically slow the advancement of Alzheimer's disease (AD), the US Food and Drug Administration (FDA) has cleared C2N Diagnostics' PrecivityAD2 blood test for patients as young as 40 who have shown some potential cognitive symptoms of the condition.

It's the first blood test cleared by the FDA to test for AD in people this young.

PrecivityAD2 is a single blood test that quickly assesses the proteins amyloid and tau, using mass spectrometry to measure plasma Aβ42/40 and p-tau217/np-tau217. The results are then scored, qualifying as negative, likely positive, or positive for AD.

“Just over a year ago, there were no FDA-cleared blood tests for Alzheimer’s, and now we have three,” Isobel Coleman, chief executive officer of the Alzheimer's Drug Discovery Foundation (ADDF), said in a statement. "This is a proof point that sustained, early investment in translational science plays a catalytic role in moving promising ideas from the lab to patients.”

In a recent clinical validation study, 1,142 symptomatic adults were tested using PrecivityAD2. The process accurately identified 97.6% of positive biomarkers. What's more, the results remained consistent even in patients with comorbidities like chronic kidney disease and diabetes, which can distort plasma amyloid samples.

[weatheriscool]